Lawrence H. Einhorn

Indiana University – Purdue University Indianapolis

Papers

2

Total Citations

66

H-Index

2

About

Lawrence H. Einhorn is a towering figure in oncology, best known for revolutionizing the treatment of testicular cancer. His landmark work introduced cisplatin-based chemotherapy, transforming a once-deadly disease into one with a cure rate exceeding 95%. This breakthrough, which has saved countless lives, remains the gold standard in germ cell tumor therapy. With over 64 citations on recent studies like his 2019 paper on adverse surgical outcomes in robotic retroperitoneal lymph node dissection, Einhorn continues to refine surgical and oncologic approaches. His multi-institutional retrospective research on early metastatic seminoma (2023) further underscores his commitment to optimizing outcomes. Beyond his prolific publications, Einhorn has received numerous accolades, including the American Cancer Society’s Medal of Honor and the Lasker Award, cementing his legacy as a pioneer. For students and researchers, his work exemplifies how rigorous clinical investigation can directly translate into life-saving therapies, making him an enduring inspiration in the fight against cancer.

Research Focus

Key Achievements

2
H-Index
2
Papers
66
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer
64 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 23
🏛 Institutions: Indiana University – Purdue University Indianapolis

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago